References
- Audeh MW, Carmichael J, Penson RT, et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245–51
- Bakos E, Evers R, Szakacs G, et al. (1998). Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem 273:32167–75
- Bansal T, Akhtar N, Jaggi M, et al. (2009). Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 14:1067–74
- Buxbaum E. (1999). Co-operative binding sites for transported substrates in the multiple drug resistance transporter Mdr1. Eur J Biochem 265:64–70
- European Medicines Agency. Guideline on the investigation of drug interactions. 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/08/WC500147164.pdf
- European Medicines Agency. Lynparza™ summary of product characteristics. 2014. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003726/human_med_001831.jsp&mid=WC0b01ac058001d124 (last accessed 3 Oct 2016)
- Evers B, Drost R, Schut E, et al. (2008). Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 14:3916–25
- Fong PC, Boss DS, Yap TA, et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123–34
- Food and Drug Administration. Guidance for industry: Drug interaction studies – study design, data analysis, implications for dosing, and labelling recommendations. 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
- Food and Drug Administration. Lynparza prescribing information: 3675412. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf
- Gelmon KA, Tischkowitz M, Mackay H, et al. (2011). Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12:852–61
- Generaux GT, Bonomo FM, Johnson M, Doan KM. (2011). Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica 41:639–51
- Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693–705
- Konig J, Muller F, Fromm MF. (2013). Transporters and drug–drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 65:944–66
- Ledermann J, Harter P, Gourley C, et al. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382–92
- Ledermann J, Harter P, Gourley C, et al. (2014). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852–61
- Niemi M, Pasanen MK, Neuvonen PJ. (2011). Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157–81
- Oza AM, Cibula D, Benzaquen AO, et al. (2015). Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16:87–97
- Pavek P, Merino G, Wagenaar E, et al. (2005). Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 312:144–52
- Rolfo C, Swaisland H, Leunen K, et al. (2015). Effect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors. Adv Ther 32:510–22
- Rottenberg S, Jaspers JE, Kersbergen A, et al. (2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105:17079–84
- Sachs-Barrable K, Thamboo A, Lee SD, Wasan KM. (2007). Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J Pharm Pharm Sci 10:319–31
- Tutt A, Robson M, Garber JE, et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235–44
- Vavricka SR, Van MJ, Ha HR, et al. (2002). Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164–72